1. Integrative oncogene-dependency mapping identifies RIT1 vulnerabilities and synergies in lung cancer.
- Author
-
Vichas A, Riley AK, Nkinsi NT, Kamlapurkar S, Parrish PCR, Lo A, Duke F, Chen J, Fung I, Watson J, Rees M, Gabel AM, Thomas JD, Bradley RK, Lee JK, Hatch EM, Baine MK, Rekhtman N, Ladanyi M, Piccioni F, and Berger AH
- Subjects
- Adaptor Proteins, Signal Transducing genetics, Animals, Cell Cycle genetics, Cell Line, Tumor, ErbB Receptors genetics, Female, Gene Knockout Techniques, High-Throughput Screening Assays, Humans, Lung Neoplasms drug therapy, Male, Mice, Molecular Targeted Therapy, Mutation, NIH 3T3 Cells, Proto-Oncogene Proteins p21(ras) genetics, Transcription Factors genetics, Xenograft Model Antitumor Assays, YAP-Signaling Proteins, ras Proteins, Lung Neoplasms genetics, Oncogenes genetics
- Abstract
CRISPR-based cancer dependency maps are accelerating advances in cancer precision medicine, but adequate functional maps are limited to the most common oncogenes. To identify opportunities for therapeutic intervention in other rarer subsets of cancer, we investigate the oncogene-specific dependencies conferred by the lung cancer oncogene, RIT1. Here, genome-wide CRISPR screening in KRAS, EGFR, and RIT1-mutant isogenic lung cancer cells identifies shared and unique vulnerabilities of each oncogene. Combining this genetic data with small-molecule sensitivity profiling, we identify a unique vulnerability of RIT1-mutant cells to loss of spindle assembly checkpoint regulators. Oncogenic RIT1
M90I weakens the spindle assembly checkpoint and perturbs mitotic timing, resulting in sensitivity to Aurora A inhibition. In addition, we observe synergy between mutant RIT1 and activation of YAP1 in multiple models and frequent nuclear overexpression of YAP1 in human primary RIT1-mutant lung tumors. These results provide a genome-wide atlas of oncogenic RIT1 functional interactions and identify components of the RAS pathway, spindle assembly checkpoint, and Hippo/YAP1 network as candidate therapeutic targets in RIT1-mutant lung cancer., (© 2021. The Author(s).)- Published
- 2021
- Full Text
- View/download PDF